Clinical Trials

Find a Trial

Trial Summary

Protocol No.IUSCC-0522
Principal InvestigatorFarag, Sherif
PhasePhase II
Age GroupAdult
TitlePhase II Trial of Inhibition Dipeptidyl Peptidase (DPP)-4 with Sitagliptin for the Prevention of Acute Graft versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
DescriptionEvaluate the efficacy of sitagliptin in reducing the incidence of grade II-IV acute Graft Versus-Host Disease (GvHD) by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell transplantation and receiving standard sirolimus and tacrolimus GvHD prophylaxis.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Patient age ≥ 18 to ≤ 60 years.
  • Patients must also receive a full myeloablative preparative regimen (Patients treated with either total body irradiation (TBI)-based or high-dose chemotherapy only regimens are eligible other than high-dose busulfan containing regimens or regimens that include anti-thymocyte globulin or other T cell depleting antibodies)
For a full list of participation criteria, please visit
Applicable Disease SitesLeukemia, other
Lymphoid Leukemia
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactPhone: (317) 278-5632